Metropolis Healthcare (METROPOLIS) investor relations material

Market context and growth drivers

• Indian diagnostics market projected to grow from $11B to $28.5B by 2034 at 11% CAGR, with a gradual shift from unorganised to organised players and rising demand for quality and advanced testing.

• Non-communicable diseases drive over 60% of mortality, increasing demand for molecular, genomic, and immunological testing.

• Company operates in 750+ towns and five international markets, with B2C contributing 57% of revenue and B2B ensuring steady lab volumes.

Strategic priorities and business model

• Focus on technology-led, scientifically differentiated growth, with automation and AI enhancing lab and customer experience.

• Five growth engines: network expansion, TruHealth wellness, specialty testing, technology, and selective M&A, supported by talent and scientific capability.

• Specialty and genomics testing targeted to reach 45% of revenue, with new-age tests and integrated diagnostics as key differentiators.

Financial performance and outlook

• FY24-26 revenue grew at 17.6% CAGR, EBITDA at 18.6% CAGR, and PAT at 22.2% CAGR, with margin reaching 24.4% despite absorbing a loss-making acquisition.

• Q1 FY27 revenue up 17% YoY, EBITDA margin up 210 bps, with B2C and rural centres leading growth.

• Three-year plan aims for faster revenue growth, improved network utilisation, higher specialty mix, and bolt-on acquisitions.